Firmonertinib plus anlotinib shows preliminary efficacy in advanced EGFR-mutant NSCLC.
Early trial shows firmonertinib plus anlotinib helps some advanced lung cancer patients
This single-arm, phase I/II trial evaluated firmonertinib combined with anlotinib in patients with advanced non-small cell lung cancer (NSCL…
Combining firmonertinib and anlotinib helped 64% of advanced lung cancer patients shrink tumors and keep disease controlled for over a year …
Nivolumab with chemotherapy and bevacizumab shows improved 4-year survival in advanced nonsquamous NSCLC
Nivolumab combination shows long-term survival benefit in advanced lung cancer trial
A Phase III randomized controlled trial of 550 patients with advanced nonsquamous NSCLC found nivolumab with carboplatin, paclitaxel, and be…
Adding nivolumab to standard lung cancer treatment helped patients live longer, with 34.7% surviving four years compared to 22.1% on placebo…
Rezivertinib improves CNS progression-free survival versus gefitinib in EGFR-mutated NSCLC with baseline CNS metastases
Rezivertinib shows longer brain metastasis control than gefitinib in lung cancer trial
A phase III randomized controlled trial in 159 treatment-naïve patients with EGFR-mutated NSCLC and baseline CNS metastases found rezivertin…
Rezivertinib kept brain cancer growth in lung cancer patients under control for nearly two years longer than gefitinib in a major trial.
Fulzerasib plus cetuximab shows 69% response in first-line KRAS-mutated NSCLC
Can a new drug combination shrink lung tumors in people with a specific KRAS mutation?
A single-arm phase 1b/2 trial in 47 treatment-naive patients with KRAS-mutated NSCLC found a confirmed objective response rate of 69% (90% C…
A new two-drug combination shrank tumors in nearly 70% of people with advanced lung cancer driven by a specific genetic mutation.
Perioperative tislelizumab plus chemotherapy improves survival in Chinese patients with resectable NSCLC
Tislelizumab with chemotherapy before surgery improves survival in Chinese lung cancer patients
In a phase III RCT of 453 Chinese adults with resectable stage II-IIIA NSCLC, perioperative tislelizumab plus neoadjuvant chemotherapy signi…
Adding tislelizumab to chemotherapy before surgery helped Chinese lung cancer patients live longer, with a 79.3% three-year survival rate ve…
Phase 3 trial of pembrolizumab versus placebo after surgery for Stage IB-IIIA NSCLC posts results
Can a drug help keep lung cancer from returning after surgery?
A Phase 3 randomized controlled trial in 1177 participants with resected Stage IB-IIIA NSCLC compared adjuvant pembrolizumab to placebo. The…
A large trial tested whether the drug pembrolizumab helps keep early-stage lung cancer from returning after surgery for over 1,100 patients.
Phase 2 trial finds no significant PFS benefit adding SABR to nivolumab in advanced NSCLC
Does adding targeted radiation to immunotherapy help advanced lung cancer?
A phase 2 randomized trial in 50 adults with metastatic NSCLC found no significant difference in 6-month progression-free survival (49% vs 4…
Adding high-dose radiation to immunotherapy did not improve outcomes or reduce side effects for advanced lung cancer patients who had alread…
Global disparities persist in access to molecular diagnostics and novel therapies for advanced NSCLC
Why does where you live still determine your lung cancer care?
A narrative review synthesizing evidence from guidelines and real-world studies describes persistent global disparities in access to molecul…
Where you live still decides if you get advanced lung cancer tests and treatments, creating a harsh reality where geography and income deter…
Phase 2 trial of neoadjuvant/adjuvant pembrolizumab in stage IB-IIIA NSCLC completes enrollment of 35 patients
Can immunotherapy before lung cancer surgery help the immune system fight the tumor?
A multi-institutional phase 2 trial has completed enrollment of 35 patients to study neoadjuvant and adjuvant pembrolizumab in stage IB, II,…
Doctors tested giving immunotherapy before lung cancer surgery to see if it safely boosts the immune system's ability to fight the tumor.
Phase 2 trial of DS-1062a in pretreated advanced NSCLC with genomic alterations posts no results
Phase 2 trial tests DS-1062a drug for advanced lung cancer with specific genetic changes
A Phase 2 interventional trial evaluated DS-1062a (6.0 mg/kg) in 137 participants with advanced/metastatic NSCLC with actionable genomic alt…
A completed Phase 2 trial tested DS-1062a for advanced lung cancer in 137 people who had already received prior chemotherapy and targeted th…
Capmatinib shows efficacy in Chinese NSCLC patients with MET exon 14 skipping mutations
Could a targeted pill help Chinese patients with a specific lung cancer mutation?
An open-label, multicenter phase II study evaluated capmatinib in 36 Chinese adult patients with advanced NSCLC harboring MET exon 14 skippi…
A targeted pill shrank tumors in Chinese lung cancer patients with a specific MET gene mutation, offering a new treatment option for this ge…
Phase III trial tests TTFields plus standard therapy for stage 4 NSCLC after platinum failure
Can adding electric fields to standard treatment help people with advanced lung cancer?
A prospective, randomized phase III trial in 291 patients with stage 4 NSCLC after platinum progression compared TTFields plus standard ther…
Doctors are testing if adding a wearable electric field device to standard drugs helps people with advanced lung cancer live longer after ch…